InvestorsHub Logo
Followers 46
Posts 4446
Boards Moderated 0
Alias Born 07/26/2010

Re: None

Monday, 12/23/2019 9:15:21 AM

Monday, December 23, 2019 9:15:21 AM

Post# of 561
CBIO 7.41 - enters an agreement with Biogen (BIIB). Friday's 8-K filing afterclose confirmed what was vague in the earlier pr:

Under the terms of the Agreement, the Company is entitled to receive from Biogen an up-front cash payment of $15 million. The Company is also eligible to receive from Biogen up to $340 million in clinical, regulatory, and commercial milestone payments. The Company will perform pre-clinical and manufacturing activities and Biogen will be solely responsible for Investigational New Drug (IND)-enabling activities, worldwide clinical development, and commercialization. Biogen will reimburse the Company for pre-clinical and manufacturing activities performed under the Agreement.

https://ih.advfn.com/stock-market/NASDAQ/catalyst-biosciences-CBIO/stock-news/81406145/current-report-filing-8-k

At 9/30 CBIO had $6.75 per share netcash remaining. This $15M upfront payment should increase their netcash and are all bills paid moving forward??? Sweetest offensive and defensive setup I see out there?
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CBIO News